Detalles de la búsqueda
1.
Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
Clin Infect Dis
; 2024 Mar 11.
Artículo
Inglés
| MEDLINE | ID: mdl-38462673
2.
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
N Engl J Med
; 384(18): 1705-1718, 2021 05 06.
Artículo
Inglés
| MEDLINE | ID: mdl-33951360
3.
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
Am J Respir Crit Care Med
; 207(10): 1376-1382, 2023 05 15.
Artículo
Inglés
| MEDLINE | ID: mdl-36790881
4.
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Clin Infect Dis
; 76(3): e580-e589, 2023 02 08.
Artículo
Inglés
| MEDLINE | ID: mdl-36041016
5.
Synthesis of methylphosphorylated oligomannosides structurally related to lipopolysaccharide O-antigens of Klebsiella pneumoniae serotype O3 and their application for detection of specific antibodies in rabbit and human sera.
Org Biomol Chem
; 21(41): 8306-8319, 2023 10 25.
Artículo
Inglés
| MEDLINE | ID: mdl-37794804
6.
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
Clin Infect Dis
; 75(4): 560-566, 2022 09 10.
Artículo
Inglés
| MEDLINE | ID: mdl-34918028
7.
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Antimicrob Agents Chemother
; 66(4): e0239821, 2022 04 19.
Artículo
Inglés
| MEDLINE | ID: mdl-35315690
8.
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
MMWR Morb Mortal Wkly Rep
; 71(8): 285-289, 2022 Feb 25.
Artículo
Inglés
| MEDLINE | ID: mdl-35202353
9.
Coronavirus Disease 2019 (COVID-19) in Americans Aboard the Diamond Princess Cruise Ship.
Clin Infect Dis
; 72(10): e448-e457, 2021 05 18.
Artículo
Inglés
| MEDLINE | ID: mdl-32785683
10.
Isoniazid and Rifampin-Resistance Mutations Associated With Resistance to Second-Line Drugs and With Sputum Culture Conversion.
J Infect Dis
; 221(12): 2072-2082, 2020 06 11.
Artículo
Inglés
| MEDLINE | ID: mdl-32002554
11.
Four-Month Rifapentine Regimens for Tuberculosis. Reply.
N Engl J Med
; 386(11): 1095-1096, 2022 03 17.
Artículo
Inglés
| MEDLINE | ID: mdl-35294823
12.
Public Health Responses to COVID-19 Outbreaks on Cruise Ships - Worldwide, February-March 2020.
MMWR Morb Mortal Wkly Rep
; 69(12): 347-352, 2020 03 27.
Artículo
Inglés
| MEDLINE | ID: mdl-32214086
13.
Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
BMC Infect Dis
; 20(1): 543, 2020 Jul 25.
Artículo
Inglés
| MEDLINE | ID: mdl-32711457
14.
Quality of reconstruction of compressed off-axis digital holograms by frequency filtering and wavelets.
Appl Opt
; 57(1): A55-A64, 2018 Jan 01.
Artículo
Inglés
| MEDLINE | ID: mdl-29328130
15.
Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
J Antimicrob Chemother
; 72(6): 1678-1687, 2017 06 01.
Artículo
Inglés
| MEDLINE | ID: mdl-28333192
16.
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.
Clin Infect Dis
; 62(4): 418-430, 2016 Feb 15.
Artículo
Inglés
| MEDLINE | ID: mdl-26508515
17.
Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012-2014.
Emerg Infect Dis
; 22(3): 491-502, 2016 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-26889786
18.
Evaluation of community-based treatment for drug-resistant tuberculosis in Bangladesh.
Trop Med Int Health
; 21(1): 131-139, 2016 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-26489698
19.
Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia.
Emerg Infect Dis
; 21(11): 2048-51, 2015 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-26488585
20.
Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010.
Emerg Infect Dis
; 21(6): 1002-11, 2015 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-25988954